Methylsulfensaeureanilid | 103375-59-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methylsulfensaeureanilid
• 英文别名: 4-methylthioaminobenzene；N-(methylthio)-aniline；Phenyl methanesulfenamide；N-methylsulfanylaniline
• CAS: 103375-59-3
• 化学式: C₇H₉NS
• 分子量: 139.221
• InChiKey: KEBXGLIHHLGNJH-UHFFFAOYSA-N

物化性质

• 沸点：
  214.0±23.0 °C(Predicted)
• 密度：
  1.133±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Methylsulfensaeureanilid 、 3-氯-2,4-戊二酮 在 sodium nitrite 作用下， 以 甲醇 为溶剂， 生成 1-chloro-1-[(4-methylthiophenyl)hydrazono]-2-propanone
  参考文献：
  名称：

  2,6-diaryl pyridazinones with immunosuppressant activity

  摘要：

  已经确定了一类具有一般结构式I的2,6-二芳基吡啶并酮，其表现出对人类T淋巴细胞的免疫抑制活性，并且可用作免疫抑制剂。##STR1##或其药用可接受的盐、水合物或晶体形式

  公开号：

  US05670504A1
• 作为产物：
  描述：

  methyl-phenylimino-propan-2-yl-λ4-sulfane 以 乙醚 为溶剂， 反应 24.0h， 生成 Methylsulfensaeureanilid
  参考文献：
  名称：

  Alkyl- und Arylsulfens�ureanilide durch Cycloelimierung von Propen aus N-Aryl-S-isopropyl-sulfimiden

  摘要：

  DOI：

  10.1007/bf00809160

文献信息

• Perfluoroalkylated aniline compound and process for producing the same
  申请人：——

  公开号：US20020198399A1

  公开（公告）日：2002-12-26

  The present invention provides an aniline derivative represented by the formula (I) 1 wherein R 1 and R 2 are each H, (C 1-12 )alkyl, (C 3-8 )cycloalkyl, hydroxy(C 1-12 )alkyl, hydroxycarbonyl (C 1-12 )alkyl, (C 1-6 )-alkoxycarbonyl(C 1-6 )alkyl, —COR 8 , wherein R 8 is H, halo-(C 1-12 )alkyl, (C 3-8 )cycloalkyl or (substituted) phenyl, COOR 9 , wherein R 9 is a halo(C 1-6 )alkyl group, (substituted) phenyl or (substituted) benzyl; R 3 , R 4 , R 5 , R 6 and R 7 are each H, halogen, OH, nitro, halo(C 1-12 )alkylthio, (substituted)amino-(C 1-2 )alkyl, (substituted) phenyl, (substituted) benzyl, amino, —N(R 10 )R 11 wherein R 10 and R 11 are each H, alkyl, cycloalkyl, (substituted) phenyl, (substituted) benzyl, —COR 8 or COOR 9 , or (C 2-27 )perfluoroalkyl, etc., and a process for producing the aniline derivative. According to the process of the present invention, perfluoroalkylaniline derivatives can be obtained by using various anilines as the substrate with a high position selectivity and high yield.

  本发明提供了一种由公式(I)表示的苯胺衍生物： 1 其中R 1 和R 2 各自是H，(C 1-12 )烷基，(C 3-8 )环烷基，羟基(C 1-12 )烷基，羟甲氧基(C 1-12 )烷基，(C 1-6 )-烷氧甲氧基(C 1-6 )烷基，—COR 8 ，其中R 8 是H，卤代-(C 1-12 )烷基，(C 3-8 )环烷基或(取代)苯基，COOR 9 ，其中R 9 是卤代(C 1-6 )烷基，(取代)苯基或(取代)苄基；R 3 ，R 4 ，R 5 ，R 6 和R 7 各自是H，卤素，OH，硝基，卤代-(C 1-12 )烷基硫，(取代)氨基-(C 1-2 )烷基，(取代)苯基，(取代)苄基，氨基，—N(R 10 )R 11 ，其中R 10 和R 11 各自是H，烷基，环烷基，(取代)苯基，(取代)苄基，—COR 8 或COOR 9 ，或(C 2-27 )全氟烷基等，以及一种用于生产该苯胺衍生物的过程。根据本发明的过程，可以通过使用各种苯胺作为底物，以高位置选择性和高收率获得全氟烷基苯胺衍生物。
• [EN] HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS<br/>[FR] ANALOGUES DIPEPTIDIQUES D'INHIBITEURS DE L'HEPATITE C
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2006007700A1

  公开（公告）日：2006-01-26

  The present invention relates to compounds of formula (I): wherein R1, R2, R4, n and m are as defined herein and R3 is selected from: (i) -C(O)OR31 wherein R31 is (C1-6)alkyl or aryl, wherein the (C1-6)alkyl is optionally substituted with one to three halogen substituents; (ii) -C(O)NR32R33, wherein R32 and R33 are each independently selected form H, (C1-6)alkyl, and Het; (iii) -SOvR34, wherein v is 1 or 2 and R34 is selected from: (C1-6)alkyl, aryl, Het, and NR32R33 wherein R32 and R33 are as defined above; and (iv) -CO(O)-R35, wherein R35 is selected from (C1-8)alkyl, (C3-7)cycloalkyl-(C1-4)alkyl, aryl, aryl-(C1-6)alkyl, Het and Het-(C1-6)alkyl, each of which are optionally substituted with one or more substituents each independently selected from halo, (C1-6)alkyl, (C3-7)cycloalkyl, aryl, Het, hydroxyl, -O-(C1-6)alkyl, -S-(C1-6)alkyl, -SO-(C1-6)alkyl, -SO2-(C1-6)alkyl, -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl, wherein the aryl portion of the -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl are each optionally substituted with one to five halo substituents. The present invention further relates to pharmaceutical compositions containing the compounds of formula (I) and methods for using these analogs in the treatment of HCV infection.

  本发明涉及以下式(I)的化合物：其中R1、R2、R4、n和m如本文所定义，R3选自：(i)-C(O)OR31，其中R31为(C1-6)烷基或芳基，其中(C1-6)烷基可选择地用一到三个卤素取代基取代；(ii)-C(O)NR32R33，其中R32和R33各自独立地选自H、(C1-6)烷基和Het；(iii)-SOvR34，其中v为1或2，R34选自：(C1-6)烷基、芳基、Het和NR32R33，其中R32和R33如上所定义；和(iv)-CO(O)-R35，其中R35选自(C1-8)烷基、(C3-7)环烷基-(C1-4)烷基、芳基、芳基-(C1-6)烷基、Het和Het-(C1-6)烷基，每种均可选择地用一种或多种取代基取代，每种取代基各自独立地选自卤素、(C1-6)烷基、(C3-7)环烷基、芳基、Het、羟基、-O-(C1-6)烷基、-S-(C1-6)烷基、-SO-(C1-6)烷基、-SO2-(C1-6)烷基、-O-芳基、-S-芳基、-SO-芳基和-SO2-芳基，其中-O-芳基、-S-芳基、-SO-芳基和-SO2-芳基的芳基部分可选择地用一到五个卤素取代基取代。本发明还涉及含有式(I)化合物的药物组合物以及在治疗HCV感染中使用这些类似物的方法。
• HETEROARYL CONTAINING BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20170240587A1

  公开（公告）日：2017-08-24

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

  本发明提供了化合物I的化合物，包括这些化合物的药物组合物以及使用这些化合物来治疗或预防由FXR和/或TGR5介导的疾病或紊乱的方法。
• Polycyclic compounds
  申请人：——

  公开号：US20030073691A1

  公开（公告）日：2003-04-17

  Novel polycyclic compounds of the formula [I], 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , ring A, ring B, X, Y and Z are as defined herein and the pharmaceutically acceptable salts thereof. These compounds have antitumor activity and useful for the treatment of cancer.

  化合物的分子式为[I]，其中R1、R2、R3、R4、R5、R6、R7、环A、环B、X、Y和Z的定义如本文所述，以及其药用盐。这些化合物具有抗肿瘤活性，可用于癌症治疗。
• LOW CHLORINE, MULTI-STAGED METHOD FOR PRODUCING CYCLOALIPHATIC DISOCYANATES
  申请人：Grund Gerda

  公开号：US20110028755A1

  公开（公告）日：2011-02-03

  Low chlorine, multi-staged method for producing cycloaliphatic diisocyanates. The invention relates to a multi-staged method for the continuous low-chlorine production of cycloaliphatic diisocyanates, comprising the synthesis of diaminodipheynl alkanes, the hydration thereof into the corresponding cycloaliphatic diamines and the subsequent conversion of cycloaliphatic diamines to the corresponding cycloalkylene biscarbamates and the thermal cleaving of the latter into the cycloaliphatic diisocyanates and alcohol.

  低氯多级生产环烷二异氰酸酯的方法。本发明涉及一种多级方法，用于连续低氯生产环烷二异氰酸酯，包括合成二氨基二苯基烷烃，将其水化为相应的环烷基二胺，然后将环烷基二胺转化为相应的环烷基二氨基甲酸酯，最后将其热解为环烷二异氰酸酯和醇。